Palbociclib/Letrozole Significantly Delayed Progression in Advanced Breast Cancer: Patients with ER-positive, HER2-negative advanced breast cancer had significant delays in progression when treated with the combination of letrozole and palbociclib, compared with letrozole alone, according to the double-blind PALOMA-2 study. However, treatment with the combination also resulted in higher rates of myelotoxic effects. Read more. Image courtesy of Pfizer.
Lower Vitamin D Levels Predict Poor Survival Outcomes in Melanoma: In patients with melanoma, lower 25-hydroxyvitamin D (vitamin D) levels were associated with poorer survival outcomes, according to a prospective study. Using 20 ng/mL as a clinical cutoff, those with deficient vitamin D levels had a significantly worse overall survival than those above that mark, with a hazard ratio (HR) of 1.44 (P = .0036). The same was true for melanoma-specific survival, with an HR of 1.37 (P = .0475). Read more. Image courtesy of the Skin Cancer Foundation.
By clicking Accept, you agree to become a member of the UBM Medica Community.